

<b>List of abbreviations</b>	5
<b>Introduction</b>	7
<b>Definitions, development and economics</b>	11
<b>Biosimilars vs reference biologics: variability and comparability</b>	23
<b>How are biosimilars approved in Europe and the USA?</b>	35
<b>Biosimilars in Europe: from regulatory approval to clinical practice</b>	61
<b>Intended copy biologics: what are they and does it matter?</b>	75
<b>Impact of intended copy biologics on medicines use</b>	93
<b>Solutions to the regulatory problem and the WHO approach</b>	101
<b>Practical steps when quality is uncertain</b>	107
<b>Biosimilars globally in endocrinology, renal medicine, hematology, oncology, and immunology</b>	115
<b>Conclusions</b>	151
<b>Index</b>	157